MENU
+Compare
CLDX
Stock ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$26.83
Change
+$0.25 (+0.94%)
Capitalization
1.78B

CLDX Celldex Therapeutics Forecast, Technical & Fundamental Analysis

Celldex Therapeutics Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
CLDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CLDX with price predictions
Dec 24, 2025

CLDX sees MACD Histogram crosses below signal line

CLDX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 15, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CLDX moved out of overbought territory on December 09, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLDX broke above its upper Bollinger Band on December 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where CLDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

CLDX moved above its 50-day moving average on December 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CLDX crossed bullishly above the 50-day moving average on November 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 249 cases where CLDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.980) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (666.667) is also within normal values, averaging (311.015).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CLDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CLDX is expected to report earnings to -100 cents per share on March 02

Celldex Therapeutics CLDX Stock Earnings Reports
Q4'25
Est.
$-1.00
Q3'25
Missed
by $0.11
Q2'25
Beat
by $0.01
Q1'25
Beat
by $0.03
Q4'24
Missed
by $0.02
The last earnings report on November 10 showed earnings per share of -100 cents, missing the estimate of -89 cents. With 221.20K shares outstanding, the current market capitalization sits at 1.78B.
A.I. Advisor
published General Information

General Information

a developer of immunotherapy technologies for the treatment of cancer and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
53 Frontage Road
Phone
+1 908 200-7500
Employees
160
Web
https://www.celldex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMLKX20.490.08
+0.39%
Shelton S&P Smallcap Index K
HGHRX39.740.15
+0.38%
Hartford Healthcare R3
OSCCX20.230.03
+0.15%
Invesco Main Street Small Cap C
EPGCX16.09N/A
N/A
Fidelity Advisor Equity Growth C
USERX30.68-0.11
-0.36%
US Global Investors Gld & Prec Mtls

CLDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+0.94%
BEAM - CLDX
55%
Loosely correlated
+1.33%
XNCR - CLDX
55%
Loosely correlated
-0.13%
RVMD - CLDX
54%
Loosely correlated
+1.15%
VRDN - CLDX
54%
Loosely correlated
+0.53%
KURA - CLDX
54%
Loosely correlated
+2.50%
More